ArticleScientific reports2021
New combination approaches to combat methicillin-resistant Staphylococcus aureus (MRSA).
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 90 citations in OpenAlex.
- LC-QTOF-MS metabolic profiling and anti-MRSA activity ofRSC advances · 2026Article
- Poly(3-hydroxybutyrate)-Based Biomimetic Materials Encapsulated with Amide Derivatives of Chlorin-e6 for Advanced Photodynamic Therapy.Nanomaterials (Basel, Switzerland) · 2026Article
- Exploring the Multifaceted Phytochemical Profile ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Phytochemical Analysis of Different Plant Organs of Bauhinia kockiana Korth. and Its Antibacterial Synergistic Interaction.Applied biochemistry and biotechnology · 2026Article
- Article
- Synthesis, spectroscopy, density functional theory study and biological activity of [Cu(phen)(L-arg)Cl]Cl·2.5HScientific reports · 2026Article
- A comprehensive review on plant-derived bioactive saponins as promising antimicrobial agents: from bioavailability challenges, molecular mechanistic insights to therapeutic applications.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Review
- Sustainable MnOPharmaceuticals (Basel, Switzerland) · 2025Article
- Green biosynthesis of bimetallic silver titanium dioxide nanoparticles using Pluchea indica with their anticancer, antimicrobial, and antioxidant activities.Scientific reports · 2025Article
- Phytochemical profiling and evaluation of antioxidant, anticancer, antimicrobial and antibiofilm activities of endophytic fungi isolated from Lavandula stricta.Scientific reports · 2025Article
- Biogenic copper and copper oxide nanoparticles to combat multidrug-resistantBiotechnology reports (Amsterdam, Netherlands) · 2025Review
- Synthesis of novel MgO-ZnO nanocomposite using Pluchea indica leaf extract and study of their biological activities.Bioresources and bioprocessing · 2025Article
- Discovery and biological evaluation of nitrofuranyl-pyrazolopyrimidine hybrid conjugates as potent antimicrobial agents targetingRSC medicinal chemistry · 2025Article
- Efficacy of Chlorogenic Acid Combined With Cefazolin Against Methicillin-ResistantThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025Article
- Assessment of the risk associated withFrontiers in microbiology · 2025Article
- Tackling carbapenem-resistantBiotechnology notes (Amsterdam, Netherlands) · 2025Article
- Antibacterial, antioxidant, cytotoxicity, and phytochemical screening of Moringa oleifera leaves.Scientific reports · 2024Article
- Nordalbergin Synergizes with NovelInternational journal of molecular sciences · 2024Article
- Green synthesis of zinc oxide nanoparticles (ZnO-NPs) by Streptomyces baarnensis and its active metabolite (Ka): a promising combination against multidrug-resistant ESKAPE pathogens and cytotoxicity.BMC microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The herbal products proved to be more promising antimicrobials even though their antimicrobial activity is milder than commercially available antibiotics. Moreover, herbal drugs may act synergistically with antibiotics to kill microbes. In this study, we aimed to enhance the activity of penicillin against MRSA through combination with the active saponin fraction isolated from the Zygophyllum album plant. Three different types of metabolites (saponins, sterols, and phenolics) have been extracted from Zygophyllum album with ethanol and purified using different chromatographic techniques. The antibacterial activity of crude extract and the separated metabolites were checked against MRSA isolates, Saponin fraction (ZA-S) was only the active one followed by the crude extract. Therefore, the compounds in this fraction were identified using ultra-high-performance liquid chromatography connected to quadrupole time-of-flight mass spectrometry (UHPLC/QTOF-MS) operated in positive and negative ionization modes. UHPLC/QTOF-MS revealed the presence of major six ursane-type tritepenoidal saponins (Quinovic acid, Quinovic acid 3β-O-β-D-quinovopyranoside, Zygophylloside C, Zygophylloside G, Zygophylloside K and Ursolic acid), in addition to Oleanolic acid. Interaction studies between saponin fraction and penicillin against MRSA were performed through the checkerboard method and time-kill assay. According to checkerboard results, only three combinations showed a fractional inhibitory concentration index less than 0.5 at concentrations of (62.5 + 312.5, 62.5 + 156.25, and 62.5 + 78.125 of penicillin and ZA-S, respectively). Time kill assay results showed that the highest reduction in log10 colony-forming unit (CFU)/ml of initial inoculum of MRSA after 24 h occurred by 3.7 at concentrations of 62.5 + 312.5 (µg/µg)/ml of penicillin and ZA-S, respectively. Thus, the combination between saponin fraction of Zygophyllum album and penicillin with these concentrations could be a potential agent against MRSA that can serve as possible model for new antibacterial drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.